Kairos Pharma’s (KAPA) Buy Rating Reaffirmed at D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $9.00 price target on the stock.

Kairos Pharma Price Performance

Shares of NYSEAMERICAN:KAPA traded down $0.03 during trading on Tuesday, hitting $1.34. 155,274 shares of the stock were exchanged, compared to its average volume of 4,532,637. Kairos Pharma has a 1-year low of $0.85 and a 1-year high of $4.00.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.